2C-B: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Link legal-status field to the USLegal: namespace |
MDElliottMD (talk | contribs) home-claude: Erowid dosing (erowid-claude source; URLs verified; em-dash clean) |
||
| Line 60: | Line 60: | ||
| voice = Commentary | | voice = Commentary | ||
}} | }} | ||
<titration slug="erowid-dose-oral" author="erowid-claude" | |||
title="Oral dose ladder (Erowid)"> | |||
Erowid's dosage documentation for oral 2C-B<ref name="erowid-2cb-dose"> | |||
Erowid. 2C-B Dosage. Erowid.org. | |||
https://www.erowid.org/chemicals/2cb/2cb_dose.shtml. | |||
Accessed 2026-05-25.</ref> reports the following tiers: | |||
* '''Threshold:''' 2-5 mg | |||
* '''Light:''' 5-15 mg | |||
* '''Common:''' 15-25 mg | |||
* '''Strong:''' 25-50 mg | |||
Timing data are not provided by Erowid for this substance. Nasal | |||
administration has been reported but Erowid does not provide separate | |||
insufflated dose tiers. Note that Erowid's common range (15-25 mg) | |||
approximates but is slightly broader than Shulgin's PiHKAL range | |||
(12-24 mg); both are consistent with the medicine's steep dose-response curve. | |||
</titration> | |||
| effects = | | effects = | ||